Subtitle
Hypofractionated Radiation Therapy for Unresectable/Locally Recurrent Intrahepatic Cholangiocarcinoma.
Subtitle
Hypofractionated Radiation Therapy for Unresectable/Locally Recurrent Intrahepatic Cholangiocarcinoma.
Proto therapy Time
December 2019
Executive summary
This study by MGH retrospectively analyzed 66 patients with unresectable intrahepatic cholangiocarcinoma (ICC) who were treated with hypofractionated proton (32 patients) or photon (34 patients) radiation therapy (HF-RT). Median RT dose was 58.05 Gy, all delivered in 15 daily fractions. The 2-year outcomes were 84% local control (LC) and 58% OS.
On multivariate analysis for OS, compared with photon RT, there was a trend towards improved survival with proton RT (HR 0.50; p = 0.05). This study concluded that HF-RT yields high rates of local control and is an effective modality to optimize biliary control for unresectable/locally recurrent ICC.
Key content topics
Top cancer treatments
Related contents
Webinar
18 October 2024
Empowering Cancer Care with Proton Therapy
Rakesh
Jalali
Srinivas
Chilukuri
Daniela
Alterio
Proton Therapy Publication
July 2024
Quantifying dose uncertainties resulting from cardiorespiratory motion in intensity-modulated proton therapy for cardiac stereotactic body radiotherapy.
Proton Therapy Publication
July 2024
Initial experience and patient tolerance of proton stereotactic body radiotherapy.
Proton Therapy Publication
March 2024
A multicenter high-quality data registry for advanced proton therapy approaches: the POWER registry.
Webinar
March 29, 2023
Hypofractionation in Proton Therapy: radiobiological bases and clinical applications
Roberto
Orecchia
Barbara
Jereczek
Daniela
Alterio
Dante
Amelio
Jiri
Kubes
Proton Therapy Publication
March 2023
A retrospective study of adjuvant proton radiotherapy for breast cancer after lumpectomy: a comparison of conventional-dose and hypofractionated dose.
Proton Therapy Publication
November 2022
Hypofractionated proton therapy for non-small cell lung cancer: Ready for prime time? A systematic review and meta-analysis.
Proton Therapy Publication
May 2022
The Role of Hypofractionation in Proton Therapy.
Proton Therapy Publication
April 2022
Outcome after Radiotherapy for Vestibular Schwannomas – Differences in Tumor Control, Symptoms and Quality of Life after Radiotherapy with Photon versus Proton Therapy.